CFTR and cystic fibrosis: Unlike ASO therapies which are targeted to very particular regions of given transcripts, application of exogenous mRNA encoding full-length wild-type CFTR has the potential to be “a one size fits all drug” applicable to patients with any CF disease-causing mutation.